MegatrendsMegatrends: not the usual suspects, but who actually profits.View megatrends →
Log inStart for free
Create watchlist

Metrics as of 10/13/2026, 06:44 PM (Berlin time), refresh in progress.

XOMA Royalty Stock

XOMA Royalty Corporation

XOMAPNASDAQMarkt
US$24.98
+0.0% today
Analyze stock

Company data

Sector
Healthcare
Industry
Biotechnology
Country
United States
CEO
Owen Patrick Hughes
Employees
14
Market cap
$301 M
IPO
16/12/2020

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also…

XOMA Royalty stock: price history

21/07/25-2.4 %21/07/26

1D

+0.0%

1W

+0.0%

1M

-1.8%

6M

-5.1%

YTD

-7.0%

1Y

-2.4%

2Y

-1.7%

5Y

-4.3%

10Y

–

Next earnings date

Next earnings date

No date known

Volatility around earnings

~11% weaker price swings than usual

Ask the agents about XOMA Royalty

Analyst assessment of XOMA Royalty

0

STRONG BUY

5

BUY

4

HOLD

0

SELL

0

STRONG SELL

9

TOTAL · Buy

As of: 12/09/2023

ANALYST FIRMRATINGACTIONDATE
HC Wainwright & Co.Buymaintain12/09/2023 (older than 12 months)
HC Wainwright & Co.Buymaintain08/08/2023 (older than 12 months)
HC Wainwright & Co.Buymaintain21/06/2023 (older than 12 months)
HC Wainwright & Co.Buymaintain14/06/2023 (older than 12 months)
HC Wainwright & Co.Buymaintain10/03/2023 (older than 12 months)
HC Wainwright & Co.Buymaintain07/10/2021 (older than 12 months)
Aegis CapitalBuymaintain08/09/2021 (older than 12 months)
WedbushOutperform → Neutraldowngrade06/09/2021 (older than 12 months)

XOMA Royalty stock metrics

P/E

15.14

P/B

2.63

EV/EBITDA

6.56

RETURN ON EQUITY

4.0%

NET MARGIN

36.2%

DEBT/EQUITY

1.1

DIVIDEND YIELD

8.6%

AS OF

31/03/2026

Free float & liquidity

FREE FLOAT

99.2%

FLOAT SHARES

11,966,158

AVG. DAILY VOLUME (30D)

2,226

Insider transactions (SEC)

ROLETRANSACTIONSHARESPRICEPLAN TYPEDATE

BVF PARTNERS L P/IL

10% ownerU3,635,758–Spontaneous16/07/2026

BVF PARTNERS L P/IL

10% ownerU2,773,545–Spontaneous16/07/2026

BVF PARTNERS L P/IL

10% ownerU412,000–Spontaneous16/07/2026

BVF PARTNERS L P/IL

10% ownerU772,000–Spontaneous16/07/2026

Franklin Heather L

DirectorJ6,269–Spontaneous14/07/2026
Page 1 / 7

Dividends

EX-DATEPAY DATEAMOUNTYIELD
02/07/202614/07/2026US$0.548.6 %
02/04/202615/04/2026US$0.548.1 %
02/01/202615/01/2026US$0.548 %
03/10/202515/10/2025US$0.548.2 %
03/07/202515/07/2025US$0.548.5 %
Page 1 / 5

Comparable stocks

Frequently asked questions about XOMA Royalty stock

What does XOMA Royalty do?

XOMA Royalty Corporation is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.

The CEO is Owen Patrick Hughes, the company employs around 14 people.

The IPO was on 16/12/2020; the stock trades on NASDAQ under the ticker XOMAP.

What do analysts say about XOMA Royalty stock?

9 analysts rate the stock, the consensus is Buy (as of 12/09/2023).

This is an external assessment, not a statement by Market Jury.

When does XOMA Royalty report next?

Around past earnings, price swings were roughly -11% stronger than usual.

Does XOMA Royalty pay a dividend?

Yes. The last dividend was US$0.54 per share, ex-date 02/07/2026, paid on 14/07/2026.

The dividend yield is 8.6% (as of 31/03/2026).

Which stocks are comparable to XOMA Royalty?

Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.

How can I get XOMA Royalty stock analyzed?

Clicking "Analyze stock" lets five strategies assess XOMA Royalty against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.

Not investment advice. Past performance is not an indicator of future results.